Regeneron and Sanofi’s Dupixent has received FDA approval for COPD, marking a significant advancement in treating this chronic lung condition. This targeted therapy addresses type 2 inflammation pathways, offering hope for patients with frequent exacerbations and improved lung function.
Eli Lilly’s new eczema treatment, Ebglyss (lebrikizumab), has shown positive results in a Phase 3b study, demonstrating its effectiveness in improving skin and itch symptoms for patients with moderate-to-severe atopic dermatitis who previously received treatment with Dupixent. The study highlights Ebglyss’s potential as a viable alternative for individuals who didn’t achieve adequate control with Dupixent.
Sanofi SA reported impressive third-quarter results, exceeding analysts’ expectations with strong sales growth fueled by its blockbuster eczema drug Dupixent, new pharmaceutical launches, and vaccine performance. The company also provided an updated outlook for 2024, reaffirming its confidence in Dupixent’s continued success and anticipating strong growth in vaccine sales.
Regeneron Pharmaceuticals and Sanofi announced positive results from multiple Phase 3 trials of their drug Dupixent, demonstrating its effectiveness in treating chronic skin conditions like chronic spontaneous urticaria (CSU) and bullous pemphigoid. These findings could lead to expanded approval for Dupixent to treat a wider range of skin conditions.
